Preview Mode Links will not work in preview mode

About IBD

Jul 11, 2022

What if we knew which patients would have severe Crohn’s disease or ulcerative colitis? And which wouldn’t? How about if we could tell which drug would work best in which patient? Knowing these things would change how inflammatory bowel disease (IBD) is diagnosed and treated. Plus, more importantly: it would improve lives. Dr Andres Hurtado-Lorenzo, Vice President of Translational research and IBD Ventures at the Crohn's and Colitis Foundation explains biomarkers and how they may play into the future of how IBD is diagnosed, managed, and treated.



Find Amber J Tresca at: